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Mining Label Data
Assessing the Presence of ortho-Phthalates in 
Pharmaceuticals and Dietary Supplements
Plasticizers known as phthalates are used in many medical and 
household products. They also are used in the coatings on timed-
release pharmaceuticals and dietary supplements, and high levels 
of phthalate metabolites have been found in subjects who take such 
products regularly. In a new study, investigators examined avail-
able data to determine the extent and scope of ortho-phthalate use 
in pharmaceutical and dietary supplement products marketed in 
the United States and Canada since 1995 [EHP 120(3):379–384; 
Kelley et al.].
Past studies in animals have shown that some ortho-phthalates 
such as di(2-ethylhexyl) phthalate (DEHP) and di-n-butyl phthalate 
(DBP) exhibit reproductive and developmental toxicity, although 
no such effects were seen for diethyl phthalate (DEP). Limited data 
suggest that all 3 compounds may adversely affect male reproductive 
health in humans. 
ortho-Phthalates are used extensively as excipients (inactive ingre-
dients) in modified-release medications taken by mouth. These 
include drugs delivered through controlled release, delayed release, 
or targeted release systems. Depending on the product, the phthalate 
coating may protect ingredients from being degraded prematurely by 
stomach acid, reduce stomach irritation, minimize aftertaste, or make 
the product easier to swallow. 
In the current study, investigators searched a variety of print and 
electronic information sources to identify brand-name and generic 
medications and dietary supplements sold in the United States and 
Canada that contained phthalates as excipients. They identified more 
than 100 such products, including 50 prescription medications, 
40 over-the-counter products, and 26 dietary supplements. Most of 
these contained DEP; 9 products contained DBP, and 1 contained 
both DEP and DBP. 
The researchers were unable to produce a truly comprehensive 
list because of the lack of a centralized data retrieval source, reliance 
on pharmaceutical companies to accurately disclose ingredient lists 
for specific products, and proprietary considerations for particular 
formulations. However, the study does give researchers an extensive, 
systematically catalogued list to refer to when conducting future stud-
ies aimed at analyzing the potential risks and human health effects 
associated with exposure to phthalates. The authors recommend that 
future studies consider the amount of phthalate that is used in vari-
ous forms of medicinal products in order to estimate ortho-phthalate 
exposure from these sources. 
Tanya Tillett, MA, of Durham, NC, is a staff writer/editor for EHP. She has been on the EHP 
staff since 2000 and has represented the journal at national and international conferences. 
Gut Check 
Do Interactions between 
Environmental Chemicals 
and Intestinal Microbiota 
Affect Obesity and 
Diabetes?
The microbiota that populate human 
intestinal tracts vary substantially 
from person to person, and mounting 
evidence suggests these inter  in  div-
id  ual variations in gut micro  biota 
affect how a person metabolizes 
chemicals they may be exposed to. A 
review of the literature on this topic 
directed attention to a new hypoth-
esis: that interactions between gut 
ecology and environmental chemi-
cals contribute to obesity and diabe-
tes [EHP 120(3):332–339; Snedeker 
and Hay]. No study has yet directly 
addressed that hypothesis, but this 
review comments on the strengths 
and weak  nesses of studies linking 
environ  mental chemicals to obesity 
and diabetes and identifies gaps in the knowledge of how gut micro-
biota may affect the metabolism of these chemicals. 
Studies reviewed by the authors found that differences in gut 
microbiota affected the toxicity of certain pharmaceuticals, including 
acetaminophen and the chemotherapy medication CPT-11. The 
authors propose that the same mechanisms may be at work with 
environ  mental chemicals. Enzymes produced by different gut microbe 
species can render ingested chemicals either more or less bioavailable, 
thereby affecting their toxicity. In reviewing evidence on 3 dozen 
suspected obesogenic and diabe-
togenic chemicals, the authors 
found that at least three-quarters 
of them may be metabolized by 
gut microbe enzymes in a way 
that affects their absorption, 
distribution, metabolism, and 
excretion.
Human studies have shown 
that obese and diabetic individ-
uals have different gut micro-
biota compositions than lean 
and nondiabetic individuals. 
Likewise, bariatric surgery was 
associated with altered gut micro-
biota. The composition of a gut’s 
microbiome may influence body 
weight by regulating fat storage, 
altering the ability of the intes-
tines to extract energy from food, 
and affecting satiety by modulat-
ing the levels of hormones that 
regulate appetite. 
The reviewers also found 
developmental links between 
gut microbiota and obesity. For 
instance, one study connected 
microbiome composition of children to their mother’s weight, 
body mass index, and degree of weight gain during pregnancy, 
while another linked differences in infant microbiota composition 
to weight gain years later. The review highlights the importance of 
understanding how differences in gut microbiota might affect the fate 
of environmental chemicals in people and influence human health 
outcomes.
Wendee Holtcamp is a science writer based in Houston, Texas.
An individual’s unique gut 
microbiota profile may affect 
how that person metabolizes 
environmental chemicals.